The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery

The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture The main questions it aims to answer are: It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration. The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score. Participants will: \- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery. This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.

NCT Number	NCT06898814
Lead Sponsor	Soren Overgaard Collaborators: University Hospital Bispebjerg and Frederiksberg, Copenhagen University Hospital at Herlev, Odense University Hospital, Musculoskeletal Statistics Unit, The Parker Institute, Svendborg Hospital
Conditions	Hip Fracture, Anemia
Enrollment	210 participants
Start Date	2025-06-09
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-09-14 (estimated)
Updated on ClinicalTrials.gov	2026-06-01